EP3378489 - MONOCLONAL ANTIBODIES AND METHODS OF USE [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 06.08.2019 Database last updated on 31.08.2024 | |
Former | Request for examination was made Status updated on 29.03.2019 | ||
Former | The application has been published Status updated on 24.08.2018 | Most recent event Tooltip | 04.06.2024 | New entry: Date of oral proceedings | Applicant(s) | For all designated states Elanco Tiergesundheit AG Mattenstr. 24A 4058 Basel / CH | [2018/39] | Inventor(s) | 01 /
Rue, Sarah Genomics Institute of the Novartis Research 10675 John Jay Hopkins Drive San Diego, CA 92121 / US | 02 /
Eckelman, Brendan Inhibrx LLC 11099 N. Torrey Pines Road Suite 1301 La Jolla, CA 92037 / US | 03 /
Deverauz, Quinn 11692 Frames Port Place San Diego, CA 92126 / US | 04 /
Nasoff, Marc 14104 Rancho Santa Fe Lakes Drive Rancho Santa Fe, CA 92067 / US | [2018/39] | Representative(s) | Greaves Brewster LLP Copa House Station Road Cheddar, Somerset BS27 3AH / GB | [N/P] |
Former [2018/39] | Alexander, Sean Matthew Eli Lilly and Company Ltd. Erl Wood Manor Sunninghill Road Windlesham, Surrey GU20 6PH / GB | Application number, filing date | 18165199.3 | 25.10.2012 | [2018/39] | Priority number, date | US201161551918P | 26.10.2011 Original published format: US 201161551918 P | US201261699300P | 11.09.2012 Original published format: US 201261699300 P | [2018/39] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | EP3378489 | Date: | 26.09.2018 | Language: | EN | [2018/39] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 18.06.2018 | Classification | IPC: | A61K39/395, A61K39/00, C07K16/00, C07K16/28, A61K45/06, G01N33/574 | [2018/39] | CPC: |
C07K16/2887 (EP,US);
A61K39/3955 (US);
A61K39/39558 (RU,US);
A61K45/06 (US);
A61P35/00 (EP);
C07K16/2896 (EP,US);
C07K16/3061 (US);
G01N33/57426 (EP,US);
C07K2317/20 (US);
C07K2317/24 (EP,US);
C07K2317/33 (EP,US);
C07K2317/52 (US);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2019/18] |
Former [2018/39] | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR | Title | German: | MONOKLONALE ANTIKÖRPER UND VERFAHREN ZUR VERWENDUNG | [2018/39] | English: | MONOCLONAL ANTIBODIES AND METHODS OF USE | [2018/39] | French: | ANTICORPS MONOCLONAUX ET PROCÉDÉS D'UTILISATION | [2018/39] | Examination procedure | 26.03.2019 | Amendment by applicant (claims and/or description) | 26.03.2019 | Examination requested [2019/18] | 26.03.2019 | Date on which the examining division has become responsible | 09.08.2019 | Despatch of a communication from the examining division (Time limit: M06) | 12.03.2020 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time | 01.06.2020 | Reply to a communication from the examining division | 13.12.2024 | Date of oral proceedings | Parent application(s) Tooltip | EP12842976.8 / EP2771694 | Request for further processing for: | The application is deemed to be withdrawn due to failure to reply to the examination report | 01.06.2020 | Request for further processing filed | 01.06.2020 | Full payment received (date of receipt of payment) Request granted | 12.06.2020 | Decision despatched | Fees paid | Renewal fee | 30.07.2018 | Renewal fee patent year 03 | 30.07.2018 | Renewal fee patent year 04 | 30.07.2018 | Renewal fee patent year 05 | 30.07.2018 | Renewal fee patent year 06 | 31.10.2018 | Renewal fee patent year 07 | 31.10.2019 | Renewal fee patent year 08 | 23.10.2020 | Renewal fee patent year 09 | 25.02.2022 | Renewal fee patent year 10 | 12.10.2022 | Renewal fee patent year 11 | 13.10.2023 | Renewal fee patent year 12 | Penalty fee | Additional fee for renewal fee | 31.10.2021 | 10   M06   Fee paid on   25.02.2022 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [XYI]WO03068821 (IMMUNOMEDICS INC [US], et al) [X] 1-4,7,13,14,16-20 * page 3, paragraph 3 - page 4, paragraph 1 * * example 9 * * example 10 * [Y] 8-10,15 [I] 5,6,11,12; | [XYI]US2005271662 (BEALL MELISSA J [US]) [X] 1-4,7,13,14,16-20 * paragraphs [0114] - [0116]; example 6 * * paragraphs [0117] - [0119]; example 7 * * paragraphs [0107] - [0108]; example 3 * * figure 8; sequence 10 * * claims 29,32 * [Y] 8-10,15 [I] 5,6,11,12; | [XYI]US2010061988 (HANSEN GENEVIEVE [US]) [X] 1-4,7,13,14,16-20 * the whole document * [Y] 8-10,15 [I] 5,6,11,12; | [Y]WO2010117760 (BOEHRINGER INGELHEIM INT [DE], et al) [Y] 8-10,15 * the whole document *; | [XYI]US2011091483 (BEALL MELISSA J [US]) [X] 1-4,7,13,14,16-20 * the whole document * [Y] 8-10,15 [I] 5,6,11,12; | [XYI]WO2011109108 (VET THERAPEUTICS INC [US], et al) [X] 1-4,7,13,14,16-20 * page 24 * * paragraphs [0117] - [0123]; example 2 * * paragraphs [0135] - [0143]; example 4 * * paragraph [0144] - paragraph [0146] * * paragraph [0154]; example 5 * [Y] 8-10,15 [I] 5,6,11,12; | [A] - RUDIKOFF S ET AL, "Single amino acid substitution altering antigen-binding specificity", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, (19820301), vol. 79, doi:10.1073/PNAS.79.6.1979, ISSN 0027-8424, pages 1979 - 1983, XP007901436 [A] 1-20 * the whole document * DOI: http://dx.doi.org/10.1073/pnas.79.6.1979 | [T] - RUE SARAH M ET AL, "Identification of a candidate therapeutic antibody for treatment of canine B-cell lymphoma", VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, (20150218), vol. 164, no. 3, doi:10.1016/J.VETIMM.2015.02.004, ISSN 0165-2427, pages 148 - 159, XP029124750 [T] 1-20 * the whole document * DOI: http://dx.doi.org/10.1016/j.vetimm.2015.02.004 | [T] - K. WEISKOPF ET AL, "Eradication of Canine Diffuse Large B-Cell Lymphoma in a Murine Xenograft Model with CD47 Blockade and Anti-CD20", CANCER IMMUNOLOGY RESEARCH, US, (20161114), vol. 4, no. 12, doi:10.1158/2326-6066.CIR-16-0105, ISSN 2326-6066, pages 1072 - 1087, XP055481448 [T] 1-20 * the whole document * DOI: http://dx.doi.org/10.1158/2326-6066.CIR-16-0105 | [T] - ITO DAISUKE ET AL, "Development of a novel anti-canine CD20 monoclonal antibody with diagnostic and therapeutic potential", LEUKEMIA & LYMP, INFORMA HEALTHCARE, UK, vol. 56, no. 1, doi:10.3109/10428194.2014.914193, ISSN 1029-2403, (20150101), pages 219 - 225, (20140616), XP009184989 [T] 1-20 * the whole document * DOI: http://dx.doi.org/10.3109/10428194.2014.914193 | [A] - JUBALA C M ET AL, "CD20 EXPRESSION IN NORMAL CANINE B CELLS AND IN CANINE NON-HODGKIN LYMPHOMA", VETERINARY PATHOLOGY, AMERICAN COLLEGE OF VETERINARY PATHOLOGISTS, US, (20050701), vol. 42, no. 4, doi:10.1354/VP.42-4-468, ISSN 0300-9858, pages 468 - 476, XP009065299 [A] 1-17 * the whole document * DOI: http://dx.doi.org/10.1354/vp.42-4-468 | [A] - IMPELLIZERI ET AL, "The role of rituximab in the treatment of canine lymphoma: An ex vivo evaluation", VETERINARY JOURNAL, BAILLIERE TINDALL, LONDON, GB, (20060501), vol. 171, no. 3, doi:10.1016/J.TVJL.2005.03.005, ISSN 1090-0233, pages 556 - 558, XP005368530 [A] 1-17 * the whole document * DOI: http://dx.doi.org/10.1016/j.tvjl.2005.03.005 | by applicant | US4816567 | US5545807 | US5545806 | US5569825 | US5625126 | US5633425 | US5661016 | WO2009080720 | WO2010022961 | US2011045536 | - JUBALA et al., Vet Pathol., (20050700), vol. 42, no. 4, pages 468 - 76 | - IMPELLIZERI et al., Vet J., (20060500), vol. 171, no. 3, pages 556 - 8 | - GRAVANIS et al., The Oncologist, (20101200), vol. 15, pages 1335 - 1343 | - TANG et al., Vet Immunol Immunopathol, (20010800), vol. 80, no. 3-4, pages 259 - 70 | - MACCULLUM et al., J. Mol. Biol, (19960000), vol. 262, no. 5, pages 732 - 745 | - "Standard conformations for the canonical structures of immunoglobulins", AL-LAZIKANI et al., J.Mol.Biol., (19970000), vol. 273, pages 927 - 948 | - AL-LAZIKANI et al., "Standard conformations for the canonical structures of immunoglobulins", J.Mol.Biol., (19970000), vol. 273, doi:doi:10.1006/jmbi.1997.1354, pages 927 - 948, XP004461383 DOI: http://dx.doi.org/10.1006/jmbi.1997.1354 | - KOHLER; MILSTEIN, Nature, (19750000), vol. 256, page 495 | - JONES et al., Nature, (19860000), vol. 321, pages 522 - 525 | - RIECHMANN et al., Nature, (19880000), vol. 332, pages 323 - 329 | - PRESTA, Curr. Op. Struct. Biol., (19920000), vol. 2, pages 593 - 596 | - VERHOEYEN et al., Science, (19880000), vol. 239, pages 1534 - 1536 | - HOOGENBOOM et al., J. Mol. Biol., (19910000), vol. 227, page 381 | - MARKS et al., J. Mol. Biol., (19910000), vol. 222, page 581 | - COLE et al., Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, (19850000), page 77 | - BOERNER et al., J. Immunol., (19910000), vol. 147, no. 1, pages 86 - 95 | - MARKS et al., Bio/Technology, (19920000), vol. 10, pages 779 - 783 | - LONBERG et al., Nature, (19940000), vol. 368, pages 856 - 859 | - MORRISON, Nature, (19940000), vol. 368, pages 812 - 13 | - FISHWILD et al., Nature Biotechnology, (19960000), vol. 14, pages 845 - 51 | - NEUBERGER, Nature Biotechnology, (19960000), vol. 14, page 826 | - LONBERG; HUSZAR, Intern. Rev. Immunol., (19950000), vol. 13, pages 65 - 93 | - GEBAUER et al., Curr. Opin. Chem. Biol., (20090000), vol. 13, no. 3, pages 245 - 255 | - NYGREN et al., FEBSJ., (20080000), vol. 275, no. 11, pages 2668 - 76 | - EBERSBACH et al., J. Mol. Biol., (20070000), vol. 372, no. 1, pages 172 - 85 | - KREHENBRINK et al., J. Mol. Biol., (20080000), vol. 383, no. 5, pages 1058 - 68 | - SKERRA, A., FEBSJ., (20080000), vol. 275, no. 11, pages 2677 - 83 | - SILVERMAN et al., Nat. Biotechnol., (20050000), vol. 23, no. 12, pages 1556 - 61 | - STUMPP et al., Drug Discov. Today, (20080000), vol. 13, no. 15-16, pages 695 - 701 | - GRABULOVSKI et al., J. Biol. Chem., (20070000), vol. 282, no. 5, pages 3196 - 3204 | - NIXON et al., Curr. Opin. Drug Discov. Devel., (20060000), vol. 9, no. 2, pages 261 - 8 | - KOIDE et al., Methods Mol. Biol., (20070000), vol. 352, pages 95 - 109 | - ZLOKARNIK et al., Science, (19980000), vol. 279, pages 84 - 8 | - CHARDES T. et al., FEBS Letters, (19990000), vol. 452, no. 3, pages 386 - 94 |